A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity
SARS-COV-2 T 세포 면역의 유도를위한 COVID-19 펩티드 백신
Clinical Trial
[키워드] All study participants
analysed
Analysis
approved
B cell
CD4
CD8
composed
conducted
CoVac-1
COVID-19
deficiency
end point
Epitopes
event
Follow-up
granuloma
IFNγ
Immunity
immunogencity
immunogenicity
induce
Local
Mild
Montanide ISA51
multifunctional
Open-label
open-label trial
participant
Patient
peptide
Peptide vaccines
peptide-based
peptide-based vaccine
peptides
Phase I
Phase I trials
primary end point
reactogenicity
receptor
safety profile
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 vaccine
SARS-CoV-2 variant
Serious Adverse Event
Serious Adverse Events
Study participants
surpassed
systemic reactogenicity
T cell
T cell epitope
T cell epitopes
T cell response
T cell responses
T cells
T helper
Toll-like receptor
Trial
vaccination
Vaccine
Vaccines
variant
Viral
viral infection
viral infections
Viral protein
Viral proteins
[DOI] 10.1038/s41586-021-04232-5 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1038/s41586-021-04232-5 PMC 바로가기 [Article Type] Clinical Trial